Laboratory:Hachioji

Laboratory:Hachioji
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
HBV genotype
|
serum
0.6 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
|
HBV DNA quantitative, IU
|
serum
1.8 |
S5F |
![]() |
![]() (21 days) |
3-5 |
PCR(Real-time PCR) Real-time PCR |
None-detected (Log IU/mL) |
HBs antigen (HQ)
|
serum
0.6 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 0.005 (IU/mL) |
HBs antibody, CLEIA
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (mIU/mL) |
HBs antibody
|
serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Passive hemagglutination(PHA) Passive hemagglutination (PHA) |
< 8 (x) |
Hepatitis B virus core antigen (HBcrAg)
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-5 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
2.1未満(LogU/mL) |
HBc antibody (IgG)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
C.O.I. < 1.0 |
IgM-HBc antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLIA Chemiluminescent immunoassay (CLIA) |
Sample/Cutoff (S/CO) < 1.00 |
HBc antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Passive hemagglutination(PHA) Passive hemagglutination (PHA) |
Negative (< 64) (x) |
HBe antigen
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
C.O.I. < 1.0 |
HBe antibody
|
serum
0.7 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
INHIBITION < 60 (%) |
HA antibody
|
serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLIA Chemiluminescent immunoassay (CLIA) |
See below. |
IgM-HA antibody
|
serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLIA Chemiluminescent immunoassay (CLIA) |
See below. |
HCV antibody, the third generation for screening
|
serum
0.7 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 1.0(-) (COI) |
HCV Grouping for interferon therapy
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
(Group) |
HCV RNA core genotype
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (3 months) |
3-5 |
RT-PCR Reverse transcriptase-polymerase chain reaction (RT-PCR) |
None-detected |
HCV RNA 1b (NS5A)
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (3 months) |
10-14 | Sanger method |
AA2209-2248: None-detected (number of variants) |
HCV RNA quantitative
|
serum
1.8 |
S5F |
![]() |
![]() (21 days) |
3-5 |
RT-PCR(Real-time PCR) Real-time PCR |
None-detected(Log IU/mL) |
Hepatitis C virus core antigen
|
serum
0.8 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLIA Chemiluminescent immunoassay (CLIA) |
< 3.0 (The lower limit of quantification) (fmol/L) |
HCV DCVresistant mutation (L31/Y93)
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (21 days) |
10-14 | Direct sequencing method +Cycleave PCR | |
HCV NS3 drug resistant mutation (D168)
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (21 days) |
10-14 |
Direct sequencing method Direct sequencing method |
|
HCV NS5B-S282 mutation
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (21 days) |
Please contact us in advance. |
Direct sequencing method Direct sequencing method |
|
IgA anti-HEV, qualitative
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-5 |
EIA Enzyme immunoassay (EIA) |
Negative |
|
serum
0.5 |
S3F,S5F |
![]() |
![]() (21 days) |
4-10 | PCR-ELMA | |
|
serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Magnetic agglutination test (MAT) |
Negative (< 8) (x) |